


03-0306

Express Mail Mailing Label No. EV668186211US

TRANSMITTAL
FORM

| | |
|---------------------------|---------------------|
| Application Serial Number | 10/737,208 |
| Filing Date | December 16, 2003 |
| First Named Inventor | Gillies, Stephen D. |
| Group Art Unit | 1646 |
| Examiner Name | Xie, Xiaozhen |
| Attorney Docket No. | LEX-023 |


ENCLOSURES (check all that apply)

- | | | |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input checked="" type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input checked="" type="checkbox"/> After Final (5 pages) <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Petition for Extension of Time <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Form PTO-1449 <input type="checkbox"/> Copies of IDS Citations <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate) | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) Copy of Form PTO-1449 dated May 13, 2005 (12 pages) |
|---|---|--|

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
 Kirkpatrick & Lockhart Nicholson
 Graham LLP
 75 State Street
 Boston, MA 02109-1808
 Tel. No.: (617) 261-3100
 Fax No.: (617) 261-3175

SIGNATURE BLOCK

Respectfully submitted,

 Date: March 2, 2006
 Reg. No. 41,640
 Tel. No.: (617) 261-3113
 Fax No.: (617) 261-3175
 Michael H. Brodowski
 Attorney for the Applicants
 Kirkpatrick & Lockhart Nicholson
 Graham LLP
 75 State Street
 Boston, MA 02109-1808



Express Mail Mailing Label No. EV668186211US

PATENT
Attorney Docket No. LEX-023

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Gillies *et al.* CONFIRMATION NO.: 6855
SERIAL NO.: 10/737,208 GROUP NO.: 1646
FILING DATE: December 16, 2003 EXAMINER: Xie, Xiaozhen
TITLE: Immunocytokine Sequences and Uses Thereof

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE UNDER 37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1646**

AMENDMENT AND RESPONSE

Dear Sir:

This paper is in response to the final Office action mailed from the U.S. Patent and Trademark Office on December 21, 2005, in relation to the above-identified application. Applicants believe no fees are necessary for consideration of this paper. If Applicants are in error, and a petition or fee is required, please consider this a conditional petition therefor, and authorization to charge Deposit Account No. 50-1721.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 4 of this paper.